198 related articles for article (PubMed ID: 16339820)
1. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2.
Atar S; Ye Y; Lin Y; Freeberg SY; Nishi SP; Rosanio S; Huang MH; Uretsky BF; Perez-Polo JR; Birnbaum Y
Am J Physiol Heart Circ Physiol; 2006 May; 290(5):H1960-8. PubMed ID: 16339820
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin.
Rosanio S; Ye Y; Atar S; Rahman AM; Freeberg SY; Huang MH; Uretsky BF; Birnbaum Y
Cardiovasc Drugs Ther; 2006 Feb; 20(1):27-36. PubMed ID: 16435070
[TBL] [Abstract][Full Text] [Related]
3. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions.
Ye Y; Lin Y; Atar S; Huang MH; Perez-Polo JR; Uretsky BF; Birnbaum Y
Am J Physiol Heart Circ Physiol; 2006 Sep; 291(3):H1158-69. PubMed ID: 16603698
[TBL] [Abstract][Full Text] [Related]
4. The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin.
Ye Y; Martinez JD; Perez-Polo RJ; Lin Y; Uretsky BF; Birnbaum Y
Am J Physiol Heart Circ Physiol; 2008 Jul; 295(1):H343-51. PubMed ID: 18469150
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury.
Birnbaum Y; Ye Y; Rosanio S; Tavackoli S; Hu ZY; Schwarz ER; Uretsky BF
Cardiovasc Res; 2005 Feb; 65(2):345-55. PubMed ID: 15639473
[TBL] [Abstract][Full Text] [Related]
6. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
Birnbaum Y; Lin Y; Ye Y; Martinez JD; Huang MH; Lui CY; Perez-Polo JR; Uretsky BF
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2891-7. PubMed ID: 17277020
[TBL] [Abstract][Full Text] [Related]
7. COX-2 mediates morphine-induced delayed cardioprotection via an iNOS-dependent mechanism.
Jiang X; Shi E; Nakajima Y; Sato S
Life Sci; 2006 Apr; 78(22):2543-9. PubMed ID: 16325209
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination.
Ye Y; Lin Y; Perez-Polo R; Huang MH; Hughes MG; McAdoo DJ; Manickavasagam S; Uretsky BF; Birnbaum Y
Am J Physiol Heart Circ Physiol; 2007 Jul; 293(1):H813-8. PubMed ID: 17416607
[TBL] [Abstract][Full Text] [Related]
9. The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.
Manickavasagam S; Ye Y; Lin Y; Perez-Polo RJ; Huang MH; Lui CY; Hughes MG; McAdoo DJ; Uretsky BF; Birnbaum Y
Cardiovasc Drugs Ther; 2007 Oct; 21(5):321-30. PubMed ID: 17620005
[TBL] [Abstract][Full Text] [Related]
10. Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart.
Birnbaum Y; Ye Y; Lin Y; Freeberg SY; Huang MH; Perez-Polo JR; Uretsky BF
Prostaglandins Other Lipid Mediat; 2007 Feb; 83(1-2):89-98. PubMed ID: 17259075
[TBL] [Abstract][Full Text] [Related]
11. COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat.
Patel HH; Hsu AK; Gross GJ
Life Sci; 2004 May; 75(2):129-40. PubMed ID: 15120566
[TBL] [Abstract][Full Text] [Related]
12. Hypercholesterolemia abrogates sevoflurane-induced delayed preconditioning against myocardial infarct in rats by alteration of nitric oxide synthase signaling.
Zhang FJ; Ma LL; Wang WN; Qian LB; Yang MJ; Yu J; Chen G; Yu LN; Yan M
Shock; 2012 May; 37(5):485-91. PubMed ID: 22266969
[TBL] [Abstract][Full Text] [Related]
13. [Cardioprotective effects of atorvastatin preconditioning via iNOS upregulation in a rabbit ischemia/reperfusion model].
Zhou Y; Chen MH; Liu JH
Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Nov; 35(11):1041-5. PubMed ID: 18269828
[TBL] [Abstract][Full Text] [Related]
14. Ventricular hypertrophy blocked delayed anesthetic cardioprotection in rats by alteration of iNOS/COX-2 signaling.
Ma L; Kong F; Ge H; Liu J; Gong F; Xu L; Hu B; Sun R
Sci Rep; 2014 Nov; 4():7071. PubMed ID: 25400168
[TBL] [Abstract][Full Text] [Related]
15. Activation of cytosolic phospholipase A2alpha through nitric oxide-induced S-nitrosylation. Involvement of inducible nitric-oxide synthase and cyclooxygenase-2.
Xu L; Han C; Lim K; Wu T
J Biol Chem; 2008 Feb; 283(6):3077-3087. PubMed ID: 18029351
[TBL] [Abstract][Full Text] [Related]
16. Reduction of infarct size by short-term pretreatment with atorvastatin.
Birnbaum Y; Ashitkov T; Uretsky BF; Ballinger S; Motamedi M
Cardiovasc Drugs Ther; 2003 Jan; 17(1):25-30. PubMed ID: 12843684
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway.
Li Q; Guo Y; Tan W; Ou Q; Wu WJ; Sturza D; Dawn B; Hunt G; Cui C; Bolli R
Circulation; 2007 Oct; 116(14):1577-84. PubMed ID: 17785622
[TBL] [Abstract][Full Text] [Related]
18. Isoflurane induces second window of preconditioning through upregulation of inducible nitric oxide synthase in rat heart.
Wakeno-Takahashi M; Otani H; Nakao S; Imamura H; Shingu K
Am J Physiol Heart Circ Physiol; 2005 Dec; 289(6):H2585-91. PubMed ID: 16006547
[TBL] [Abstract][Full Text] [Related]
19. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of iNOS protects the aging heart against beta-adrenergic receptor stimulation-induced cardiac dysfunction and myocardial ischemic injury.
Li D; Qu Y; Tao L; Liu H; Hu A; Gao F; Sharifi-Azad S; Grunwald Z; Ma XL; Sun JZ
J Surg Res; 2006 Mar; 131(1):64-72. PubMed ID: 16154595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
